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Ethnopharmacological  relevance:  The  study  was  aimed  at evaluating  medicinal  and therapeutic  poten-
tials  of  two  Lycopodiaceae  species,  Lycopodium  clavatum  (L.)  and  Lycopodium  thyoides  (Humb.  & Bonpl.
ex  Willd),  both  used  in South  American  folk  medicine  for  central  nervous  system  conditions.  Alkaloid
extracts  were  evaluated  for  chemical  characterization,  acetylcholinesterase  and  antioxidant  activities.
Materials  and methods:  The  alkaloid  extracts  obtained  by  alkaline  extraction  were  determined  for  each
species  by GC/MS  examination.  The  evaluation  of  the  anticholinesterase  and  the  antioxidant  activities
of  the  extracts  were  tested  by  determining  in  vitro  and  ex  vivo  models.  Effects  on  acetylcholinesterase
(AChE) were  tested  in  vitro  using  rat  brain  homogenates  and  ex vivo after  a single  administration  (25,
10  and  1 mg/kg  i.p.)  of  the  alkaloid  extracts  in mice.  The  in  vitro  antioxidant  effects  were  tested  for  the
2-deoxyribose  degradation,  nitric  oxide  (NO)  interaction,  2,2-diphenyl-1-picryl  hydrazyl  (DPPH)  radical
scavenging  activity  and  total  reactive  antioxidant  potential  (TRAP).  After  an  acute  administration  (25  and
10 mg/kg  i.p.)  of the extracts  in  middle-aged  (12  months)  mice,  the antioxidant  effects  were  estimated
through  the  thiobarbituric  acid  reactive  substances  test  (TBARS),  and  the  antioxidant  enzymes  activities
for  catalase  (CAT)  and  superoxide  dismutase  (SOD)  were  measured.
Results:  AChE  activity  was  inhibited  in  vitro  by  the  alkaloid-enriched  extracts  of both  Lycopodium  species
in  a dose  and  time-dependent  manner  in  rat  cortex,  striatum  and  hippocampus.  A signiﬁcant  inhibition
was  also  observed  in  areas  of  the  brain  after  acute  administration  of  extracts,  as  well  as  decreased  lipid
peroxidation  and  increased  CAT  activity  in  the cortex,  hippocampus  and  cerebellum.  A  moderate  antiox-
idant activity  was  observed  in  vitro  for the  extracts.  Chemically,  the main  alkaloids  found  for  the  two
species  were  lycopodine  and  acetyldihidrolycopodine.
Conclusion:  This  study  showed  that  the  biological  properties  of  the  folk  medicinal  plants  Lycopodium
clavatum  and  Lycopodium  thyoides  include  AChE  inhibitory  activity  and  antioxidant  effects,  two  possible
Alzhemechanisms  of action  in  
. IntroductionAlzheimer’s disease (AD) is the most common neurodegen-
rative disease of this century and the most prevalent cause of
ementia among the elderly. About 4.6 million new cases of
Abbreviations: AD, Alzheimer’s disease; AChE, acetylcholinesterase; AE, alkaloid
xtract; i.p., intraperitoneal; LC, Lycopodium clavatum; LT, Lycopodium thyoides.
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dementia are reported every year worldwide, and it is estimated
that 71% of dementia cases will occur in the developing countries
by 2040 (Ferri et al., 2005; Kalaria et al., 2008). This irreversible
neurological disorder is characterized by memory impairment, cog-
nitive dysfunction, behavioral disturbances and deﬁcits in activities
in daily living (Cummings et al., 1988).
In the past decade, treatment for AD has largely involved
Open access under the Elsevier OA license.replacement of neurotransmitters that are known to be lacking,
mostly based on the inhibition of acetylcholinesterase (AChE), an
important approach that is founded on the cholinergic hypothesis
for the disease (Francis et al., 1999). As one of the most remarkable
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iochemical changes in AD patients is a reduction of acetylcholine
evels in the hippocampus and cortex of the brain, the use of
holinesterase inhibitors is the most commonly used treatment
or the symptoms of mild AD, improving the cholinergic deﬁcit
Lahiri et al., 2002). However, the drugs that are currently used for
he treatment of AChE inhibitory activity (e.g. rivastigmine, galan-
hamine and donepezil) are extremely limited and possess some
onsiderable side effects, related to cholinergic stimulation in brain
nd peripheral tissues (Thompson et al., 2004; Fang et al., 2008).
ecently, multiple lines of evidence indicate that reactive oxygen
pecies are associated with the pathogenesis of AD, given that some
ellular characteristics of this disease are either causes or effects
f oxidative stress (Zhu et al., 2004; Sultana et al., 2006). Antioxi-
ants may  therefore be applied as neuroprotective agents (Moreira
t al., 2005), since oxidative damage can be observed before the
ormation of speciﬁc pathological -amyloid plaques. Considering
he complex pathology of AD, the current strategies to develop new
gents focus on compounds with multiple potencies, and plants are
n important source of these compounds.
A number of plants have been used in traditional medicine
emedies to treat memory and cognitive disorders, such as Huperzia
errata (Qian Ceng Ta), which has been used for centuries in China
or the treatment of contusions, strains, swelling and schizophre-
ia (Skolnick, 1997). Huperzine A and B, two alkaloids found in
his species, have proved to be potent, reversible and selective
nhibitors for AChE activity (Liu et al., 1986; Ayer, 1991). More-
ver, huperzine A displayed a remarkable activity on memory and
earning (Zhang et al., 1991), as well as in vivo antioxidant activ-
ty against free radicals and -amyloid-induced cell toxicity (Wang
t al., 2001; Xiao et al., 2002). For this reason, this compound has
een marketed in China as a new drug for AD, and some synthetic
erivatives are being developed as drug candidates in China and
urope (Ma et al., 2007). Since then, Lycopodium alkaloids, a group
f metabolites occurring in the family Lycopodiaceae, have become
 new potential source of pharmacologically interesting natural
roducts that have led to the identiﬁcation of over 200 alkaloids
rom 54 Lycopodium species so far (Ma and Gang, 2004).
Lycopodium clavatum (L.) and Lycopodium thyoides (Humb. &
onpl. ex Willd) (Lycopodiaceae), commonly known as “club
osses”, are creeping perennial species found in almost all parts
f the world, although they are considered to be montane plants
n the Neotropics (Øllgaard, 1992). Both species are well known for
heir rich alkaloid content, which has been extensively reviewed
Ayer and Dikko, 1974; MacLean, 1985; Ma  and Gang, 2004) and
haracterized by the absence of huperzines, more commonly found
n the Huperzia genus. Aerial parts of Lycopodium clavatum are pop-
larly used as carminatives, laxatives and diuretics (Schauenberg
nd París, 1972; Nun˜ez and Cantero, 2000); the entire plant is
sed in South America as an aphrodisiac (Hurrel and de la Sota,
996) and in China for the treatment of mental disorders (Duke
nd Ayensu, 1985). The Quechuas, an Andean ethnic group from
cuador, use infusions of Lycopodium thyoides as a traditional
edicine to treat parturition disorders, and the whole plant is
elieved to act as a central nervous system stimulant for young chil-
ren with motor problems, in order to improve their resistance to
he labor (Ellemann, 1990; Navarrete et al., 2006). Therefore, in this
tudy, the hypothesis that the alkaloid extracts from Lycopodium
pecies can inhibit the activity of the enzyme AChE, and also display
ntioxidant activities, was tested.
. Materials and methods.1. Plant material
Lycopodium thyoides and Lycopodium clavatum were collected
n the city of Bom Jesus, Rio Grande do Sul, Brazil in Novemberarmacology 139 (2012) 58– 67 59
2007, and identiﬁed by Prof. Dr. Sérgio L. Bordignon, Fundac¸ ão La
Salle. The voucher specimens (collection numbers HAS 45875 and
HAS 45878, respectively) were deposited in the Herbarium of the
Fundac¸ ão Zoobotânica do Rio Grande do Sul, Porto Alegre, Brazil.
2.2. Preparation of the total alkaloid extracts (AE)
The dried and ground aerial parts from Lycopodium thy-
oides (1.69 kg) and Lycopodium clavatum (1.35 kg) were separately
extracted with n-hexane using a Soxhlet extractor. Afterwards,
defatted plant material was exhaustively macerated with methanol
and the resulting crude extracts were dried under reduced pres-
sure. Each extract was then suspended in 5% HCl and partitioned
with CH2Cl2. The aqueous layers were alkalinized with 0.1 N NaOH
until pH 12, and then extracted again with CH2Cl2; the organic
layers were dried over Na2SO4 and evaporated to give the crude
alkaloid extracts AELT (Lycopodium thyoides) and AELC (Lycopodium
clavatum).
2.3. Chemical composition
The alkaloid extracts were submitted to GC–MS  in order to sep-
arate and identify the present components, by means of an Agilent
7890A directly coupled to a quadrupole mass spectrometer Agilent
5975C and equipped with a capillary column HP  30, 30 m in length.
The analysis was performed using an injection volume of 0.5 L
with He as a carrier, with a ﬂow rate of 1 mL/min. Temperature
program: 230 ◦C (2 min), 230–250 ◦C at 20 ◦C/min, 250 ◦C (2 min),
250–280 ◦C at 5 ◦C/min and 280 ◦C (5 min). The temperatures of
the injector, interface and ion source were 300, 280 and 280 ◦C,
respectively. The ionization energy was  70 eV and individual identi-
ﬁcation of the samples was made by matching scores from our own
MS library of Lycopodium alkaloids, comparison with the literature
data and standards co-injections. Retention indexes of the alkaloids
were recorded by co-injecting 1 L of 1 mg/mL  of the standard cali-
bration n-hydrocarbon mixture (C9–C36) and 1 L of 1 mg/mL AELC
and AELT solutions, using the temperature program: 60–300 ◦C at
3 ◦C/min. The nuclear magnetic resonance (NMR) spectra in CDCl3
of the main alkaloids were obtained using a Bruker DPX400 spec-
trometer, operating at 400 MHz  for 1H and 100 MHz  for 13C.
2.4. Animals
Experiments were performed using adult male Wistar rats (60
days old, weighing 240–260 g) and Swiss albino male mice (CF1
strain, 3 and 12 months old, weighing 35–50 g); all obtained from
the Fundac¸ ão Estadual de Produc¸ ão e Pesquisa em Saúde (FEPPS).
Animals were maintained under controlled temperature (23 ± 1 ◦C)
and light-dark cycles of 12 h, with free access to food and water.
The research protocols with animals followed throughout our study
were designed to minimize suffering and limit the number of ani-
mals sacriﬁced. The project was approved (#2007942, 2008) by the
University Ethics Committee.
2.5. Drugs and reagents
Acetylthiocholine iodate, 5,5′-dithiobis-(2-nitrobenzoic acid)
(DTNB), AAPH (2,2-azobis[2-methylpropionamidine]dihydrochlo-
ride), luminol (5-amino-2,3-dihydro-1,4-phthalazinedione), 2-
deoxyribose, glycine, Griess reagent, sodium nitroprusside,
huperzine A and DPPH (2,2-diphenyl-1-picrylhydrazyl) were
obtained from Sigma–Aldrich Chemical Co. (St. Louis, MO,  USA).
Dimethyl sulfoxide (DMSO) and the buffer salts were purchased
from Merck (Darmstadt, Germany). All other chemicals and organic
solvents were of analytical grade. Stock solutions of AELC and AELT
6 hnoph
w
c
o
1
s
ﬁ
2
E
f
h
2
a
w
b
c
s
a
p
D
(
t
i
h
5
a
m
i
i
c
V
L
3
c
2
(
s
1
b
b
s
w
e
(
2
2
e
d
m
(
a
A
w
s
s
cerebella were dissected out, brain tissues were homogenized0 E.L. Konrath et al. / Journal of Et
ere initially dissolved in DMSO and further diluted to various con-
entrations in 20 mM phosphate buffer immediately before use, in
rder to achieve ﬁnal concentrations of DMSO of not greater than
%. For the intraperitoneal (i.p.) administrations, extracts were dis-
olved in DMSO and saline solution 0.9% g (w/v) NaCl to obtain the
nal concentrations in a 20% (v/v) DMSO solution.
.6. Anticholinesterasic activity assays
AChE activity was measured by the colorimetric method of
llman et al. (1961) with some minor modiﬁcations, adapted
or determining the enzyme activity in supernatants of brain
omogenates.
.6.1. In vitro analysis for AChE activity
Rats were separately decapitated, the brains quickly removed
nd placed on an ice-cold plate. Cortices, striata and hippocampi
ere dissected, weighed and homogenized in cold 10 mM  Tris–HCl
uffer, pH 7.2, containing 160 mM sucrose. The homogenates were
entrifuged at 10,000 × g for 10 min  at 4 ◦C, and the resulting clear
upernatants were used as enzyme sources that were divided into
liquots and stored at −20 ◦C. Brieﬂy, enzyme samples in 20 mM
hosphate buffer (pH 7.4) were incubated in the presence of 10 mM
TNB solution with different concentrations of each AE in buffer
ﬁnal concentrations from 50 to 1000 g/mL). The enzyme reac-
ion was initiated by the addition of 0.8 mM acetylthiocholine
odide after the pre incubation times of 0, 15 and 30 min. Substrate
ydrolysis was monitored by the formation of a yellow anion of
-thio-2-nitrobenzoic acid at 415 nm,  every 30 s during 2.5 min, by
 SpectraMax 190, 96-well plate reader. Enzyme activity was  esti-
ated through differences in A/min, and the degrees of inhibition
n each brain area and incubation time were calculated by compar-
son with its control (1% DMSO, results expressed as percentages of
ontrol); every experiment was performed in triplicate.
The kinetic parameters Km (Michaelis–Menten constant) and
max (maximal velocity) were determined by means of a
ineweaver–Burk plot over a substrate range of 0.01–0.08 mM after
0 min  of incubation of striatum samples with three different con-
entrations of AELC and AELT (50, 100 and 250 g/mL).
.6.2. Ex vivo analysis for AChE activity
Three-months old mice were randomly divided into 9 groups
n = 6) and each received a single i.p. injection (0.1 mL/10 g) of saline
olution, vehicle (20% DMSO), AELC (25, 10 and 1 mg/kg), AELT (25,
0 and 1 mg/kg) or huperzine A (0.5 mg/kg). Animals were killed
y decapitation 60 min  after each administration. Subsequently,
rains were removed; cortices and hippocampi were dissected
eparately and processed as described above. Total AChE activity
as measured as triplicates in aliquots of brain homogenates, the
nzymatic inhibition is expressed as the percentage of the control
DMSO-treated mice).
.7. Antioxidant activity assays
.7.1. Assay of 2-deoxyribose degradation
The formation of OH (hydroxyl radicals) was  indirectly
stimated by the spectrophotometric measurement of the 2-
eoxyribose oxidative degradation, through the production of
alondialdehyde, which condensates with 2-thiobarbituric acid
TBA) (Hermes-Lima et al., 1994). The reaction was  carried out in
 20 mM  phosphate buffer (pH 7.2) medium containing AELC and
ELT at ﬁnal concentrations ranging between 50 and 2500 g/mL
ith 5 mM 2-deoxyribose and 100 mM H2O2. The reaction was
tarted by the addition of Fe2+ (6 mM ﬁnal concentration) to the
olutions and was carried out for 15 min  at room temperature. Thearmacology 139 (2012) 58– 67
reaction was  stopped by the addition of 4% phosphoric acid fol-
lowed by 1% TBA (in 50 mM NaOH). Solutions were boiled for 15 min
at 100 ◦C and then cooled at room temperature. The absorbance
was  measured at 532 nm and percent values were determined by
comparing the absorbance of control (Fenton reagents) and test
samples.
2.7.2. Scavenging activity of the nitric oxide (NO) radical
The interaction of the alkaloid extracts (in ﬁnal concentrations
of between 50 and 2500 g/mL) with nitric oxide was  assessed by
the nitrite detection method (Green et al., 1982). NO was generated
from spontaneous decomposition of 200 nM sodium nitroprus-
side in 20 mM phosphate buffer (pH 7.4). Nitric oxide interacts
with oxygen to produce stable products, leading to the forma-
tion of nitrites, which were measured by the Griess reaction. The
reaction mixture containing 10 mM sodium nitroprusside in phos-
phate buffer and the extracts were incubated at 37 ◦C for 1 h. An
aliquot was  taken and homogenized with Griess reagent (0.1% -
naphthylethylenediamine in water and 1% sulfanilic acid in 5%
H3PO4). The concentration of nitrite was assayed at 540 nm and
calculated with reference to the absorbance of the standard nitrite
solutions. The inhibition results were expressed as percentages in
relation to the non-treated control.
2.7.3. DPPH radical scavenging activity
The free radical scavenging effect of the extracts was  assessed
by the discoloration of a methanolic solution of 1,1-diphenyl-2-
picrylhydrazyl radical (DPPH), as previously reported (Mensor et al.,
2001). The extracts were assayed in a range of 10–500 g/mL. The
quenching of free radicals by extracts was  evaluated spectrophoto-
metrically at 517 nm against the absorbance of the DPPH radical. A
freshly prepared DPPH solution (0.1 mM)  was used for the assays,
samples were dissolved in methanol and the methanolic solution of
DPPH served as a control. The degree of discoloration indicates the
free radical scavenging efﬁciency of the substances. The percentage
of DPPH discoloration was  calculated as previously described.
2.7.4. Total reactive antioxidant potential (TRAP) assay
An adapted method of TRAP to measure luminol-enhanced
chemiluminescence (Lissi et al., 1992) was  used to determine
the capacity of the alkaloid extracts to trap a ﬂow of water-
soluble peroxyl radicals produced through thermal decomposition
of ABAP (2,2′-azobis (2-amidinopropane) dihydrochloride). Brieﬂy,
the reaction mixture contained the free radical source (ABAP,
10 mM)  and 4 mM luminol in the 0.1 M glycine buffer (pH 8.6).
The incubation of this mixture at 20 ◦C generates an almost con-
stant light intensity that was  measured in a scintillation counter
(Beckman), working in the out of coincidence mode. For the
determination of the free radical scavenging potential, increasing
concentrations of AELC and AELT in methanol were added to the
system (from 50 to 2500 g/mL). The results of the chemilumines-
cence emission were expressed as area under the curve (AUC).
2.8. Ex vivo antioxidant assay
Mice (twelve-months old) were divided into 6 groups (n = 6).
Saline solution, vehicle (20% DMSO), AELC (25 and 10 mg/kg)
or AELT (25 and 10 mg/kg) were injected i.p. (0.1 mL/10 g). Ani-
mals were decapitated at 60 min  after drug administration and
each brain was  quickly excised. Hippocampi, cerebral cortices andin 10 vol. of ice-cold 20 mM phosphate buffer (pH 7.4) contain-
ing EDTA (1 mM)  and phenylmethylsulfonyl ﬂuoride (1 mM). The
homogenates were centrifuged at 10,000 × g for 10 min; the super-
natants were employed for the assays.
hnopharmacology 139 (2012) 58– 67 61
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.8.1. Lipid peroxidation assay
Lipoperoxidation was evaluated by thiobarbituric acid reactive
ubstances (TBARS) tests during an acid-heating reaction, as pre-
iously described (Draper and Hadley, 1990). Aliquots of samples
ere incubated with 10% trichloroacetic acid and 0.67% thiobar-
ituric acid. The mixture was heated (25 min) in a boiling water
ath. TBARS was determined by reading the absorbance of the
ink-colored complex formed in a spectrophotometer at 532 nm.
,1,3,3-Tetramethoxypropane, which is converted to malondialde-
yde, was used as standard.
.8.2. Determination of antioxidant enzyme activity
Catalase (CAT) activity was assayed, as described by Aebi (1984).
rieﬂy, homogenates were incubated with 10% ethanol and 10%
riton and the activity was assayed at 37 ◦C by determining the rate
f degradation of H2O2 at 240 nm in 20 mM potassium phosphate
uffer (pH 7.0). One unit is deﬁned as 1 pmol of H2O2 consumed per
inute and the speciﬁc activity is reported as units per mg  protein.
uperoxide dismutase (SOD) activity was accessed by quantifying
he inhibition of superoxide-dependent adrenaline auto-oxidation
n a spectrophotometer at 480 nm (Boveris, 1984) and the results
re expressed as units of SOD/mg of protein.
.9. Protein assay
All results were normalized by the protein concentrations,
hich were determined by Peterson’s modiﬁcation of the proce-
ure of Lowry et al. (1951) using bovine serum albumin as standard.
.10. Statistical analysis
Results are expressed as mean ± standard error mean (S.E.M.).
ifferences between the treatments and controls were evaluated by
NOVA followed by Duncan’s multiple range test whenever neces-
ary; linear regression was further used to verify the dose–response
elationship. A p < 0.05 was considered to be signiﬁcant. Data
elated to Km and Vmax were analyzed by one-way ANOVA.
. Results
.1. Chemical composition
The yield of the extracts was 0.34% and 0.38% of dried
aterials for Lycopodium clavatum and Lycopodium thyoides,
espectively. GC–MS analysis performed for the extracts of each
pecies revealed the presence of a number of known Lycopodium
lkaloids (Fig. 1) belonging to the lycopodane and ﬂabellidane
roups in different percentages. Both species had lycopodine
nd acetyldihydrolycopodine as their main alkaloids, as well as
ycodoline, anhydrolycodoline, lycodine and -obscurine, as shown
n Figs. 1A and 2A.  Additionally, N-methyllycodine and traces of
lavolonine were detected in Lycopodium clavatum, whereas for
ycopodium thyoides the alkaloid ﬂabellidine was  found. The 1H
nd 13C NMR  spectra of the main compounds found in extracts,
ycopodine and acetyldihydrolycopodine is shown in Table 2.
.2. Acetylcholinesterase inhibition
No signiﬁcant differences in AChE activity (A/min) were found
ith phosphate buffer or DMSO over time. Both alkaloid extracts
f Lycopodium signiﬁcantly inhibited AChE activity in vitro in a
ose and time-dependent manner in all brain structures studied
Figs. 2 and 3). At 30 min  of incubation with AELC, there were
ose/effect associations with Pearson’s coefﬁcients as follows:
2 = 0.9227 (p < 0.001) for cortex (Fig. 2A), r2 = 0.8731 (p < 0.001)
or striatum (Fig. 2B) and r2 = 0.9139 (p < 0.001) for hippocampusFig. 1. Structures of the alkaloids detected in the alkaloid extracts of Lycopodium
clavatum (AELC) and Lycopodium thyoides (AELT).
(Fig. 2C), while for AELT r2 = 0.8752 (p < 0.001) was  found for cortex
(Fig. 3A), r2 = 0.8904 (p < 0.001) for striatum (Fig. 3B) and r2 = 0.8868
(p < 0.001) for hippocampus (Fig. 3C). Whereas the AChE inhibition
seems to be stabilized after 15 min  of incubation in the presence
of AELC in the cortex, with AELT it continues to drop thereafter. As
for striatum, treatment with AELC also promotes a stabilization of
enzymatic inhibition after 15 min, the same effect was  found for
higher concentrations of AELT (500 and 1000 g/mL), while for 50
and 250 g/mL, a continuous drop in inhibition was  observed. In
the hippocampus, treatment with both alkaloid extracts seemed
not to affect AChE inhibition over time. In cortex, striatum and hip-
pocampus, the enzymatic activities reached a maximal inhibition
of 73.3%, 62% and 59% in the presence of AELC, whereas for AELT this
effect was 81.6%, 75% and 78.5%, respectively, both at 1000 g/mL
after 30 min  of incubation.
The double-reciprocal Lineweaver–Burk plot for rat striatal
acetylcholinesterase assays with 30 min  of incubation (Fig. 4)
indicated that, in the presence of increasing concentrations of
AELC (50, 100 and 250 g/mL), Vmax values are reduced (from
0.32 to 0.23, 0.16 and 0.12 M of acetylthiocholine hydrolyzed/mg
62 E.L. Konrath et al. / Journal of Ethnopharmacology 139 (2012) 58– 67
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total reactive antioxidant potential. At the ﬁnal concentration ofest; (a) p < 0.05 vs. 50 g/mL, (b) p < 0.05 vs. 250, (c) p < 0.05 vs. 500, ANOVA/Duncan;
#) p < 0.05 vs. previous incubation time, ANOVA/Duncan.
f protein/min, respectively) and Km values are increased (from
.05 to 0.07, 0.09 and 0.12 M,  respectively). In the case of
ELT, the same concentrations also induced a decrease in
max (from 0.26 to 0.17, 0.13 and 0.11 M of acetylthiocholine
ydrolyzed/mg of protein/min, respectively), and an augment in
m (from 0.05 to 0.07, 0.09 and 0.11 M),  a pattern common to
ompetitive/noncompetitive type inhibitors.
Table 1 shows the effects of a single administration of the alka-
oid extracts (25, 10 and 1 mg/kg, i.p.) on AChE activity in the cortex
nd hippocampus of mice. As observed, treatment with the extracts
orrelated with enzymatic inhibition in all of the brain structures
tudied; when treated with AELC, decreases in AChE activity were in
he range of 46.5, 37.2 and 20% (cortex) and 43, 18.7 and 6.2% (hip-
ocampus), respectively for each dose, while for AELT, decreases inEach value represents mean ± S.E.M. (n = 5). *p < 0.05 vs. control, paired Student’s t
test; (a) p < 0.05 vs. 50 g/mL, (b) p < 0.05 vs. 250, (c) p < 0.05 vs. 500, ANOVA/Duncan;
(#) p < 0.05 vs. previous incubation time, ANOVA/Duncan.
enzymatic activity were in the order of 43.5, 40.7 and 28.3% (cor-
tex) and 54.7, 33.6 and 10% (hippocampus). At 0.5 mg/kg, huperzine
A showed an inhibitory effect of 64.3% for cortex and 47.5% for
hippocampus.
3.3. Antioxidant activities
Table 2 summarizes the antioxidant effects of each AE and
the reference free radical scavenger boldine against 2-deoxyribose
degradation, nitric oxide production, DPPH discoloration and2500 g/mL, the inhibitory power against 2 deoxyribose degrada-
tion comprised 25–32%, and for nitric oxide production 50–60% for
AELC and AELT. Both extracts were also able to reduce the DPPH
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Table 1
Effects of an acute administration of Lycopodium clavatum and Lycopodium thyoides
AE (1, 10 and 25 mg/kg i.p.) and huperzine A (0.5 mg/kg i.p.) on AChE activity in mice
cortex and hippocampus.
Treatment groups Dose (mg/kg) AChE inhibition (%)
Cortex Hippocampus
AELC 25 46.8 ± 2.9* 44.2 ± 1.5*
10 37.8 ± 2.1* 20.4 ± 1.6*
1 21.4 ± 0.9* 6.7 ± 0.9
AELT 25 48.9 ± 1.7* 50.2 ± 1.3*
10 41.7 ± 2.3* 31.5 ± 2.4*
1 29.6 ± 2.2* 9.8 ± 1.1
Huperzine A 0.5 62.1 ± 2.5* 49.2 ± 0.9*
All assays were performed in triplicate. Enzyme inhibition is expressed as percent-
age  of control (DMSO-treated mice). Each value represents mean ± S.E.M. (n = 6).
genus (Lycopodiaceae) and collected in Brazil: Lycopodium clava-
T
I
a
Rions (0.01–0.08 mM)  from striatum samples in the absence or presence of AE (50,
00 and 250 g/mL) of Lycopodium clavatum (A) and Lycopodium thyoides (B).
adical at all tested concentrations; however, due to the turbidity
n test conditions, concentrations of higher than 500 g/mL could
ot be assayed. In the TRAP assay, the extracts acted as peroxyl scav-
ngers, diminishing the chemiluminescence with induction times
hat were proportional to the concentrations added. In addition,
 single i.p. administration of AELC and AELT (25 and 10 mg/kg)
o 12-months old mice induced changes in all indexes of oxida-
ive stress studied, with different patterns found in different brain
egions. A signiﬁcant decrease in lipoperoxidation (TBARS levels,
ig. 5) was observed in the cortex, hippocampus and cerebellum
able 2
nhibition proﬁle of activities of the Lycopodium clavatum and Lycopodium thyoides AE ag
ctivity and total reactive antioxidant potential (TRAP) assays as free radical scavengers.
Treatment groups Dose (g/mL) 2-Deoxyribose degradation 
AELC 2500 25.3 ± 2.7*
1000 8.6 ± 1.5 
500 4.9 ± 0.7 
250 3.2 ± 0.3 
50 1.1 ± 0.02 
AELT 2500  32.0 ± 2.1*
1000 25.4 ± 1.1*
500 20.1 ± 1.3*
250 12.8 ± 0.4*
50 8.4 ± 0.4*
Boldine 100  43.4 ± 2.7*
50 18.5 ± 0.9*
10 5.2 ± 0.4 
1 1.3 ± 0.4 
esults are expressed as % of activity relative to the corresponding control (mean ± S.E.M
* p < 0.05 as compared to control group.
+ p < 0.05 as compared to previous dose.ANOVA followed by Duncan’s test.
* p < 0.05; signiﬁcant from control.
for all extracts analyzed. In terms of antioxidant enzymes activity,
SOD activity was  signiﬁcantly increased only in the cerebellum of
AELT treated mice (Fig. 6A), while CAT activity was  enhanced in
all brain structures after treatment with both AE (Fig. 6B). More-
over, the SOD/CAT ratio was found to be signiﬁcantly decreased
in the cortex, hippocampus and cerebellum of AELC treated mice
(Fig. 6C), while AELT promoted a decrease only at the higher dose,
with the exception of the cortex, which showed a decrease in the
enzymatic ratio at all doses.
4. Discussion and conclusions
The use of inhibitors of the acetylcholinesterase enzyme is
currently widely accepted as the ﬁrst line pharmacotherapy for
symptomatic relief of mild to moderate AD, through an increase
in acetylcholine levels at the synaptic site in the brain, improving
the memory and cognitive deﬁcits of the patients (Giacobini, 2003;
Loizzo et al., 2008). Some potent inhibitors of AChE are derived from
natural sources and most of them belong to the chemical class of
alkaloids, including galanthamine, obtained from Amaryllidaceae
species, and huperzine A, the most studied Lycopodium alkaloid.
As such, the present study reports, for the ﬁrst time, on the in
vitro and ex vivo antioxidant and anticholinesterasic activities of
the alkaloid extracts of two  species belonging to the Lycopodiumtum (L.) and Lycopodium thyoides (Humb. & Bonpl. ex Willd). These
plants are well known for their alkaloid content, which has been
extensively reviewed, and decoctions of the entire plants are used
ainst 2-deoxyribose degradation, nitric oxide production, DPPH radical scavenging
Nitric oxide production DPPH decoloration TRAP assay
57.2 ± 1.6* – 81.4 ± 1.8*,+
53.5 ± 1.1* – 72.5 ± 1.1*,+
49.2 ± 0.7*,+ 91.7 ± 0.6*,+ 45.3 ± 1.5*,+
24.4 ± 1.3*,+ 85.6 ± 4.1*,+ 24.0 ± 0.8*,+
2.9 ± 0.2 50.1 ± 3.2* 5.1 ± 0.2
48.6 ± 2.1* – 84.9 ± 2.1*,+
43.3 ± 0.9*,+ – 74.7 ± 1.9*,+
31.7 ± 1.9* 83.1 ± 1.3*,+ 33.5 ± 1.3*,+
23.5 ± 1.2* 68.7 ± 0.9*,+ 21.2 ± 1.2*,+
19.1 ± 0.9* 43.8 ± 0.2* 4.9 ± 0.5
79.1 ± 3.8* 97.8 ± 2.9* 70.9 ± 3.5*
59.4 ± 2.1* 70.4 ± 2.5* 55.9 ± 1.9*
22.7 ± 1.3* 53.8 ± 0.2* 18.8 ± 1.5*
12.0 ± 0.9* 15.1 ± 0.4* 3.1 ± 0.4
., 6–8 experiments run in triplicate). ANOVA followed by Duncan’s test.
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cerebellum) (nmol MDA/mg protein). Data are referred to ﬁve separated experime
roup, +p < 0.05 as compared to previous dose.
n folk medicine for CNS-related conditions, as nerve tonics and for
otor disorders (Duke and Ayensu, 1985; Navarrete et al., 2006).
ome previous studies have found that a crude plant extract of
ycopodium clavatum growing in Turkey displayed a signiﬁcant
nhibitory effect on AChE in vitro (49.8%) at the concentration of
000 g/mL (Orhan et al., 2004); a bio-assay guided fractionation
f the plant extract indicated triterpenoid -onocerin as the main
ompound responsible for this activity (Orhan et al., 2003). Later, in
ontrast to these studies, no anti-AChE activity was found for this
ompound, and another triterpenoid, lyclavatol, was found to pos-
ess some inhibitory effect, although the presence of this compound
oes not fully explain the activity of the Lycopodium clavatum crude
xtract (Rollinger et al., 2005). Furthermore, an alkaloid extract
or the same species was found to possess a signiﬁcant in vivo
nti-inﬂammatory activity, where the major alkaloid found for this
xtract was lycopodine, followed by dihydrolycopodine and lyco-
ine, all of them belonging to lycopodane group (Orhan et al., 2007).
n the other hand, to our knowledge no biological studies have
een reported in the literature with the Lycopodium thyoides species
o far.
In the present study, we report that the alkaloid extracts of both
he Lycopodium clavatum and Lycopodium thyoides species have the
bility to inhibit AChE and display antioxidant properties, as evalu-
ted by in vitro and ex vivo assays. The AChE activity was found to be
nhibited in the rat cortex, hippocampus and striatum homogenates
ncubated in vitro with AELC and AELT (50–1000 g/mL); a signiﬁ-
ant (≈10–50%) decrease in AChE activity was also observed ex vivo
n these memory relevant brain structures, as evaluated at 60 min
fter a single AELC and AELT (25, 10 and 1 mg/kg i.p.) administration
o adult (3 months) mice. Although further experiments are needed
or a deﬁnitive conclusion, the AChE inhibition induced by both
lkaloid extracts seems to be dose and time-dependent, with AELT
isplaying a higher inhibitory activity when compared to AELC. Dif-
erent effects on enzymatic inhibition may  be related to varying
oncentrations of several molecular AChE forms in particular tis-
ues or brain regions, favoring interactions with particular types of
he enzyme in each (Bisso et al., 1991). Of note, i.p. administration
f huperzine A, obtained from the Chinese medicinal herb Huperzia
errata, resulted in various degrees of AChE activity inhibition in
he rat hippocampus, cortex, striatum and hypothalamus (Tang
t al., 1994; Cheng and Tang, 1998), consistent with our ﬁndings
or this alkaloid in the hippocampus and cortex (inhibition of 49.2
nd 62.1%, respectively). Also, the observed levels of inhibition are
omparable to those reported for donepezil and tacrine (30–46%) byaline group were 0.26 ± 0.04 (cortex), 0.19 ± 0.03 (hippocampus) and 0.27 ± 0.01
n in triplicate (ANOVA followed by Duncan’s test). *p < 0.05 as compared to saline
using the same analytical method (Kosasa et al., 1999). The com-
petitive/noncompetitive mode of inhibition, as suggested by the
Lineweaver–Burk plots, indicates that active alkaloids in extracts
are able to interact with both the enzyme active center and the
enzyme–substrate complex. Interestingly, compounds with noto-
rious efﬁcacy for the symptomatic treatment of AD, such as tacrine
galanthamine and donepezil, are also of the mixed type of inhi-
bition (Snape et al., 1999; Khalid et al., 2005), as well as some
plant extracts with reported neuroprotective effects (Siqueira et al.,
2003).
Increasing evidence supports the role of oxidative damage to
biomolecules in the pathogenesis of AD patients, suggesting that
antioxidants may  be recognized as a potential treatment for the
disease (Lleó et al., 2006). In this scenario, the beneﬁts of multi-
factorial medicines have been advocated, stimulating the search
for new anti-AChE and antioxidant drugs, especially those derived
from natural sources. Relevant to this discussion, our in vitro antiox-
idant tests revealed that extracts had poor activity against the
formation of hydroxyl radicals a harmful radical formed in vivo, but
were more potent in decreasing the concentration of nitrite after
the spontaneous decomposition of sodium nitroprusside, indicat-
ing that the alkaloids of AELC and AELT may  be able to scavenge
nitric oxide. The scavenging effect on DPPH, which is related to lipid
peroxidation (Rekka and Kourounakis, 1991), revealed a stronger
antioxidant effect for the extracts, and may  be attributed to their
capacity of trapping free radicals by donating a hydrogen atom.
TRAP assay is commonly associated with the ability of a given com-
pound to scavenge peroxyl radicals, superoxide or luminol-derived
radicals (Lissi et al., 1992), indicating the presence of alkaloids in the
assayed extracts with dose-dependent antioxidant action, although
less potent than the reference scavenger alkaloid boldine.
Additionally, acute treatments with AELC or AELT in middle-
aged mice were found to reduce oxidative stress damage in speciﬁc
brain areas. This is an important step to verify a physiological con-
tribution to the cellular defenses against free radicals, by detecting
the interaction of the extracts with the antioxidant systems of the
brain samples. Our data showed that extracts diminished the for-
mation of TBARS, an index of lipid peroxidation, in the cortex,
hippocampus and striatum. Moreover, both AE enhanced CAT activ-
ity, therefore avoiding the accumulation of hydrogen peroxide. As
for SOD, this enzyme’s activity was  only signiﬁcantly enhanced in
the cerebellum after the administration of AELT, indicating that
extracts did not reach the brain areas studied, at least in signif-
icant amounts, or even that the extracts have a selective capacity
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2rotein  (cerebellum). The mean CAT values from saline groups were 1.1 ± 0.08 (cort
eferred to ﬁve separated experiments run in triplicate (ANOVA followed by Dunca
or speciﬁc brain structures. The activity ratios between the antiox-
dant enzymes, such as SOD/CAT ratio, have been considered to be
n index of oxidative status (Palomero et al., 2001). As such, the
igh activity of CAT combined with the decrease in SOD function
n most brain regions might allow an imbalance in the physio-
ogic generation of oxygen reactive species that in many cases
ct as cell signaling elements, compromising Ca2+ inﬂux and the
esicular trafﬁc through cell membranes (Halliwell, 2006; Forman,
007).0 ± 0.03 (hippocampus) and 1.2 ± 0.04 U enzyme/mg protein (cerebellum). Data are
t). *p < 0.05 as compared to saline group, +p < 0.05 as compared to previous dose.
Although some alkaloid extracts of Lycopodiaceae species, such
as Huperzia saururus (Ortega et al., 2004) and Lycopodium complana-
tum (Orhan et al., 2009), have been already tested for in vitro AChE
inhibitory activity, no study has been carried out on the anti-AChE
effect for the constituents of the currently analyzed species, with
the exception of anhydrolycodoline (IC50 = 191 M)  and lycodoline,
which displayed poor effects against the enzyme (Halldorsdottir
et al., 2010). Therefore, the inhibitory activities of the pure alka-
loids are currently being studied in order to identify the active
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ompound(s) in the extracts. As expected, huperzine A and B were
ot detected in the AE, pointing out that the biological activity
ound may  be due to other Lycopodium alkaloids. In addition, the
onstituents present in the alkaloid extracts, responsible for the
nticholinesterase and antioxidant activities found after a single i.p.
dministration may  have different activities and/or access different
reas of brain, suggesting that pharmacokinetic studies to evaluate
he distinct distribution of the compounds should be carried out.
The major ﬁnding of this study was that AELC and AELT demon-
trate efﬁcacy in crossing the blood–brain barrier, which may  be
n important property for medications for neurodegenerative dis-
ases. In addition, alkaloid extracts had signiﬁcant AChE inhibition
nd antioxidant effects (as demonstrated by ex vivo and in vitro ani-
al  models) in brain areas relevant to cognitive functions. Thus,
his study provides further evidence that Lycopodium clavatum and
ycopodium thyoides possess multiple modes of action that are rel-
vant to cognitive disorders, corroborating their traditional use by
ocal communities in South America as medicines.
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